Fig. 3

DRα1-mMOG-35-55 treatment of transient MCAO: a Four daily 100 μg DRα1-mMOG-35-55 treatments significantly decreased infarct volumes in DR*1501-Tg male mice after 60 min MCAO and 96 h of reperfusion in cortex (CTX), caudateputamen (CP), and total hemisphere (HMSPHR) (*p ≤ 0.05). b Representative 2,3,5-triphenyltetrazolium chloride stained cerebral sections after 96 h of reperfusion are shown following 1 h of MCAO. c Treatment of female DR*1501-Tg mice required four daily injections of 1 mg DRα1-mMOG-35-55 to significantly reduce infarct volumes (*p ≤ 0.05). d DRα1-MOG-35-55 treatment reduced the absolute number of infiltrating cells, e activated CD11b⁺CD45^high cells, and f their CD74 surface expression in the ischemic brain in male mice 96 h after MCAO. *p < 0.05, **p < 0.01, ***p < 0.001. Panels (a, b, d, e) reprinted by permission from RightsLink: Springer, Metabolic Brain Disease, A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke, Benedek et al., copyright 2014 [72]. Panel (c) reprinted from “Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke,” by Pan et al., 2014, Translational Stroke Research, 5(5):577-85, copyright Pan et al., 2014 [63]